46 citations,
January 1996 in “Journal of The American Academy of Dermatology”
People with late-stage HIV-1 often experience a specific type of hair loss linked to multiple factors, including nutritional issues and immune responses.
The conversation discusses Dr. BlakeBloxham's experiment with Verteporfin for hair loss, with one person suggesting more doctors should try it as it seems beneficial. Another comment notes that results at 4-5 months were not very impressive.
The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. BlakeBloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.
The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.
Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.
Daily microneedling at 0.25mm before applying minoxidil is debated, with some suggesting weekly microneedling is safer and more effective. Concerns include potential skin damage and systemic absorption, while alternatives like tretinoin are considered safer for enhancing minoxidil absorption.